The estimated reading time for this post is 4 Minutes
Last year’s studies in the United States showed how 45% of Americans had tried marijuana at least once in their lives, data that in the process of state legalization represent the largest since 1969. In that first year of that realizationsame study , the data obtained was 4%. At the same time, 64% of the population considers that it should be legalized, and it is also thegreatest support it receives in almost 50 years of analysis (at that time only 12% supported legalization). This happens in a country where, despite being still banned at the federal level, there are already eight states and the District of Columbia that have fully legalized it, which means that just over 20% of Americans live in a state where they can enjoy legally of the use of marijuana.Without entering into the moral and political debate on the use of Cannabis sativa (its scientific name), and although the use as a recreational drug is more popular, what really matters about this legalization revolves around itsmedicinal and therapeutic use.
The benefits range from certain neuroprotective properties, to having the capacity to stop the metastasisof some types of cancer, from helping to stop the advance ofAlzheimer’s , HIV in the body and even to be able to combat depression processes. And all this has not gone unnoticed neither for the medical community nor for the investment community.According to another study by New Frontier Data , the marijuana industry could create more than200,000 jobs in the United States in 2020. That would coincide with an annual growth rate of 16% between recreational and medical consumption. In this way, it would go from the current 7,000 million USD to 24,000 million in 2025.
The impact on many businesses is clear and goes from growers and packers of the plant, to those who dispense it for medical or recreational use, passing through the manufacturers of the so-calledCBD , which are a kind of medicines to treat patients with inflammations , chronic pain and depression .Using real data and not previous predictions, the truth is that reality exceeded expectations and in 2017 the turnover closed above USD 10 billion (compared to an estimated 7,970 million). Some analysts commented that the United States was creating the first scalable cannabis industry while the rest of the world was waiting to see the results. Not in vain until Spain could anticipate the debate opened by the UN on the legalization of cannabis .An investor duly documented, and eager to participate in the growth of this possible new green gold can access the market in various ways.
The first and most direct, involves the investment in listed shares whose main activity revolves around the medical industry of marijuana .There are not many options totally focused on the activity, but some examples could be Cronos Groupquoted on the Nasdaq (CRON) or the Canadian Aurora Cannabis Inc(ACB) whose behavior, compared to Amazon or Google, has been spectacular in the last half year.The second way to participate in this sector could be through quoted funds. Right now, one of the most interesting (and most risky) given its composition, is the ETF Management Group Alternative Harvest (MJ). This instrument includes 30 companies that are dedicated to the legal cultivation of cannabis, to distribution for medical or recreational purposes or to their legal production.
Although the member companies belong to North America , none that cultivate or distribute marijuana in the United States is included because of the existence, at the federal level, of the aforementioned prohibition. It isCanada ‘s main source location of those companies whose minimum profit off 50% of this business.This being the case and without this being any offer or invitation to acquire assets of this sector, there is no doubt that the wide medical possibilities that cannabis offers, could well turn it into a kind of green gold in the future. The advantages are innumerable from that point of view and its legalization for this purpose, increasingly approved by the population. And when it comes to investing, those are the characteristics that every investor, according to his profile, must analyze in order to look for diversification and source ofpossible alpha .
#heathcare #medical #medicalcare #pharmaceuticals #healthcareprofessional #nurses #healthprofessionals
Liked this content and would like yours written from scratch? Press “Order Now” to place your new order Now!
Blade Research
